234 related articles for article (PubMed ID: 30565179)
1. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.
Cazzaniga ME; Munzone E; Bocci G; Afonso N; Gomez P; Langkjer S; Petru E; Pivot X; Sánchez Rovira P; Wysocki P; Torri V
Adv Ther; 2019 Feb; 36(2):381-406. PubMed ID: 30565179
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
[TBL] [Abstract][Full Text] [Related]
3. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
Cazzaniga ME; Pinotti G; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Fiorentini G; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Melegari E; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Clivio L; Torri V;
Breast; 2019 Dec; 48():7-16. PubMed ID: 31470257
[TBL] [Abstract][Full Text] [Related]
4. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
Trevisan B; Pepe FF; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Clivio L; Torri V; Cazzaniga ME;
Sci Rep; 2023 Jul; 13(1):12255. PubMed ID: 37507480
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
Cazzaniga ME; Munzone E; Montagna E; Pappagallo G
Expert Rev Anticancer Ther; 2018 Aug; 18(8):805-814. PubMed ID: 29902087
[TBL] [Abstract][Full Text] [Related]
6. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
7. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
Pepe FF; Cazzaniga ME; Baroni S; Riva F; Cicchiello F; Capici S; Cogliati V; Maggioni C; Cordani N; Cerrito MG; Malandrin S
BMC Cancer; 2022 Sep; 22(1):956. PubMed ID: 36068484
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration
Scagliotti A; Capizzi L; Cazzaniga ME; Ilari A; De Giorgi M; Cordani N; Gallazzi M; Bruno A; Pelosi G; Albini A; Lavitrano M; Grassilli E; Cerrito MG
Front Oncol; 2022; 12():998274. PubMed ID: 36531071
[TBL] [Abstract][Full Text] [Related]
10. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
11. Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.
Cazzaniga ME; Capici S; Cordani N; Cogliati V; Pepe FF; Riva F; Cerrito MG
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36012949
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy for advanced breast cancer patients.
Cazzaniga ME; Dionisio MR; Riva F
Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
[TBL] [Abstract][Full Text] [Related]
13. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
14. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
Xu B; Sun T; Wang S; Lin Y
Expert Rev Anticancer Ther; 2021 Jan; 21(1):71-79. PubMed ID: 33054438
[TBL] [Abstract][Full Text] [Related]
15. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
[TBL] [Abstract][Full Text] [Related]
16. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
17. Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
Caparica R; De Angelis C; Fêde Â; Werutsky G; de Azambuja E
Expert Rev Anticancer Ther; 2020 Jul; 20(7):563-573. PubMed ID: 32536212
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
19. Metronomic Chemotherapy.
Cazzaniga ME; Cordani N; Capici S; Cogliati V; Riva F; Cerrito MG
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066606
[TBL] [Abstract][Full Text] [Related]
20. Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
Li JW; Zuo WJ; Ivanova D; Jia XQ; Lei L; Liu GY
Breast Cancer Res Treat; 2019 Jan; 173(2):407-415. PubMed ID: 30361875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]